Skip to main
IMTX

Immatics NV (IMTX) Stock Forecast & Price Target

Immatics NV (IMTX) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immatics NV has positioned itself advantageously in the biotechnology sector through extensive patent protections for its innovative target discovery platforms and antigenic peptide targets, enhancing its competitive edge. The company has demonstrated promising clinical outcomes, specifically a 50% objective response rate and a 6.0 months median progression-free survival in advanced melanoma patients, which considerably surpasses standard-of-care benchmarks. With a revised global risk-adjusted sales forecast of €711.3 million for 2035, Immatics is poised for significant revenue growth driven by its strategic collaborations and effective therapies in oncology.

Bears say

Immatics NV faces significant risks that could adversely impact its financial outlook, including potential setbacks in research and development, regulatory hurdles, and competition from emerging companies. The company's reliance on successful clinical trial outcomes is tempered by the possibility that even if endpoints are met, they may not satisfy regulatory criteria, leading to delays in product approval. Additionally, the necessity for further capital raises poses a risk of share dilution, which could further undermine investor confidence and negatively affect stock performance.

Immatics NV (IMTX) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immatics NV and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immatics NV (IMTX) Forecast

Analysts have given Immatics NV (IMTX) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Immatics NV (IMTX) has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immatics NV (IMTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.